TDM-105795 / Therapeutics Inc, TechnoDerma Medicines, Cutia Therap - LARVOL DELTA

A Phase I Clinical Trial Evaluating the Safety, Tolerability, and Pharmacokinetics of CU-40101 Liniment in Single and Multiple Doses in Adult Male Androgenic Alopecia Subjects (clinicaltrials.gov) - P1 | N=80 | Completed | Sponsor: Cutia Therapeutics（Wuxi）Co.,Ltd | Recruiting ➔ Completed

Trial completion • Alopecia • Dermatology • Immunology

Study of TDM-105795 Following Topical Administration in Male Subjects With Androgenetic Alopecia (clinicaltrials.gov) - P2 | N=71 | Completed | Sponsor: Technoderma Medicines Inc. | Recruiting ➔ Completed | Trial completion date: Apr 2024 ➔ Jan 2024

Trial completion • Trial completion date • Alopecia • Dermatology • Immunology

A Phase I Clinical Trial Evaluating the Safety, Tolerability, and Pharmacokinetics of CU-40101 Liniment in Single and Multiple Doses in Adult Male Androgenic Alopecia Subjects (clinicaltrials.gov) - P1 | N=62 | Recruiting | Sponsor: Cutia Therapeutics（Wuxi）Co.,Ltd | Trial primary completion date: Jul 2023 ➔ Nov 2023

Trial primary completion date • Alopecia

Study of TDM-105795 Following Topical Administration in Male Subjects With Androgenetic Alopecia (clinicaltrials.gov) - P2 | N=72 | Recruiting | Sponsor: Technoderma Medicines Inc. | Not yet recruiting ➔ Recruiting

Enrollment open • Alopecia

Technoderma Medicines Initiates TDM-105795 Androgenetic Alopecia Phase 2 Clinical Trial (PRNewswire) - "Technoderma Medicines, Inc...is pleased to report that the Company has begun dosing patients in its Androgenetic Alopecia (AGA) Phase 2 clinical trial (NCT05802173) of topical TDM-105795 solution... Approximately 12 U.S. clinical sites are currently participating in this study under an open IND with FDA."

Trial status • Alopecia • Dermatology

Study of TDM-105795 Following Topical Administration in Male Subjects With Androgenetic Alopecia (clinicaltrials.gov) - P2 | N=72 | Not yet recruiting | Sponsor: Technoderma Medicines Inc.

New P2 trial • Alopecia

A Study of TDM-105795 in Male Subjects With Androgenetic Alopecia (AGA) (clinicaltrials.gov) - P1 | N=32 | Completed | Sponsor: Technoderma Medicines Inc. | Recruiting ➔ Completed | Trial completion date: Oct 2022 ➔ Feb 2023

Trial completion • Trial completion date • Alopecia

A Phase I Clinical Trial Evaluating the Safety, Tolerability, and Pharmacokinetics of CU-40101 Liniment in Single and Multiple Doses in Adult Male Androgenic Alopecia Subjects (clinicaltrials.gov) - P1 | N=62 | Recruiting | Sponsor: Cutia Therapeutics（Wuxi）Co.,Ltd | Not yet recruiting ➔ Recruiting

Enrollment open • Alopecia

CU-40101-101 Following a Fixed-volume Topical Single Administration in Healthy Male Subjects With Androgenetic Alopecia (clinicaltrials.gov) - P1 | N=62 | Not yet recruiting | Sponsor: Cutia Therapeutics（Wuxi）Co.,Ltd

New P1 trial • Alopecia

A Study of TDM-105795 in Male Subjects With Androgenetic Alopecia (AGA) (clinicaltrials.gov) - P1 | N=32 | Recruiting | Sponsor: Technoderma Medicines Inc. | Not yet recruiting ➔ Recruiting

Enrollment open • Alopecia

A Phase 1 Study of TDM-105795 Topical Solution in Male Subjects With Androgenetic Alopecia (AGA) (clinicaltrials.gov) - P1 | N=30 | Completed | Sponsor: Technoderma Medicines Inc. | Recruiting ➔ Completed

Trial completion • Alopecia